Icotinib

Generic Name
Icotinib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C22H21N3O4
CAS Number
610798-31-7
Unique Ingredient Identifier
9G6U5L461Q
Background

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...

Indication

Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

First Posted Date
2013-04-30
Last Posted Date
2015-07-15
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
100
Registration Number
NCT01843647
Locations
🇨🇳

Zhejiang cancer hospital, Hangzhou, Zhejiang, China

Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer

First Posted Date
2012-11-12
Last Posted Date
2017-03-01
Lead Sponsor
Guangdong Association of Clinical Trials
Target Recruit Count
176
Registration Number
NCT01724801
Locations
🇨🇳

Guangdong General Hospital, Guangzhou, Guangdong, China

🇨🇳

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Phase 4
Suspended
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Icotinib
First Posted Date
2012-11-02
Last Posted Date
2015-05-22
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
20
Registration Number
NCT01720901
Locations
🇨🇳

Xiangya Hospital, Central-South Univercity, Changsha, Hunan, China

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Phase 3
Completed
Conditions
NSCLC
Interventions
Drug: Chemotherapy
Drug: Icotinib
First Posted Date
2012-11-01
Last Posted Date
2019-07-05
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
296
Registration Number
NCT01719536
Locations
🇨🇳

The First Affiliated Hospital of Anhui Medical Univercity, Hefei, Anhui, China

🇨🇳

Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China

🇨🇳

Beijing Hospital for Chest Tumors & Tuberculosis Diseases, Beijing, Beijing, China

and more 18 locations

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

First Posted Date
2012-09-20
Last Posted Date
2012-09-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
20
Registration Number
NCT01688713
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Phase 4
Conditions
Non-Small Cell Lung Cancer
Interventions
Drug: Icotinib
First Posted Date
2012-07-20
Last Posted Date
2015-09-09
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
35
Registration Number
NCT01646450
Locations
🇨🇳

Shanghai Chest Hospital Affliated to Shanghai Jiaotong Univercity, Shanghai, Shanghai, China

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Phase 1
Completed
Conditions
Nasopharyngeal Carcinoma
First Posted Date
2012-02-16
Last Posted Date
2018-04-17
Lead Sponsor
Taizhou Hospital
Target Recruit Count
48
Registration Number
NCT01534585
Locations
🇨🇳

Taizhou Hospital, Wenzhou Medical College, Taizhou, Zhejiang, China

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

First Posted Date
2012-01-25
Last Posted Date
2014-02-17
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
15
Registration Number
NCT01516983
Locations
🇨🇳

West China Hospital, Chengdu, Sichuan, China

Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Metastatic Cancer
Interventions
Drug: Icotinib
First Posted Date
2012-01-23
Last Posted Date
2014-07-23
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
20
Registration Number
NCT01514877
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Phase 4
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Drug: Icotinib
First Posted Date
2011-11-04
Last Posted Date
2014-02-17
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
Target Recruit Count
32
Registration Number
NCT01465243
Locations
🇨🇳

307 Hospital of People's Liberation Army（PLA）, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy